Premium
ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R 2 ‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma
Author(s) -
Vitolo U.,
Witzig T.E.,
Gascoyne R.D.,
Scott D.W.,
Zhang Q.,
Jurczak W.,
Özcan M.,
Hong X.,
Zhu J.,
Jin J.,
Belada D.,
Bergua J.M.,
Piazza F.,
Mócikova H.,
Molinari A.L.,
Yoon D.H.,
Cavallo F.,
Tani M.,
Izutsu K.,
Kato K.,
Czuczman M.,
Hersey S.,
Kilcoyne A.,
Russo J.,
Hudak K.,
Zhang J.,
Chiappella A.,
Nowakowski G.S.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.5_2629
Subject(s) - lenalidomide , medicine , diffuse large b cell lymphoma , chop , rituximab , clinical endpoint , placebo , gastroenterology , lymphoma , vincristine , oncology , pathology , randomized controlled trial , chemotherapy , cyclophosphamide , multiple myeloma , alternative medicine